SWP
TGTX icon

Stratos Wealth Partners’s TG Therapeutics TGTX Stock Holding History

Stratos Wealth Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,755
Closed -$303K – 1449
2023
Q4 		$303K Buy
17,755
+7,325
+70% +$85.1K 0.01% 1078
2023
Q3 		$87.2K Buy
+10,430
New +$145K ﹤0.01% 1235
2018
Q4 		– Sell
-200
Closed -$1K – 2335
2018
Q3 		$1K Buy
+200
New +$2.29K ﹤0.01% 2888
2018
Q2 		– Sell
-630
Closed -$9K – 2415
2018
Q1 		$9K Buy
+630
New +$8.05K ﹤0.01% 2386

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stratos Wealth Partners's TGTX Position: Q1 2024 in Review

Stratos Wealth Partners sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 17,755 shares — an estimated $303K sold.

Stratos Wealth Partners first reported a position in TGTX in Q1 2018 and held it in 4 quarters. The position peaked at $303K in Q4 2023. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Stratos Wealth Partners reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Stratos Wealth Partners sold 17,755 TG Therapeutics shares in Q1 2024, an estimated $303K.
  • Stratos Wealth Partners first reported a position in TG Therapeutics in Q1 2018 and held it in 4 quarters.
  • Stratos Wealth Partners's TG Therapeutics position peaked at $303K in Q4 2023.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Stratos Wealth Partners's 13F filing for Q1 2024, filed 16 Apr 2024.